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___________________________________________________________________________ 
Suomalaisessa eturauhassyövän seulontatutkimuksessa, joka on suurin komponentti Eurooppalaista 
eturauhassyövän seulonnan monikeskustutkimusta, todettiin pieni, ei-tilastollisesti merkitsevä 
alentuma eturauhassyöpäkuolleisuudessa tutkittaessa prostata spesifiseen antigeeniin (PSA) 
perustuvaa eturauhassyövän seulontaa verrattuna eurooppalaiseen vastaavaan tutkimukseen. 
PSA:han perustuva eturauhassyövän seulonta on kuitenkin ristiriitaista siihen liittyvän 
ylidiagnostiikan vuoksi. Ylidiagnostiikka aiheuttaa turhia kustannuksia ja kärsimystä niin 
yhteiskunnalle kuin potilaille. Aikaisemmissa tutkimuksissa todettiin tulehduskipulääkkeiden 
laskevan veren PSA-pitoisuuksia, todennäköisimmin vähentämällä intraprostaattisesta 
tulehduksesta johtuvia PSA:n nousuja. Omassa tutkimuksessani tutkimme, vaikuttaako 
eturauhassyövän seulonnan kohdistaminen tulehduskipulääkkeiden käyttäjiin eturauhassyöpäriskiin 
ja – kuolleisuuteen.  
Tutkimuksen aineistona toimi Suomalaisen eturauhassyövän seulontatutkimuksen 78615 miestä, 
jotka oli satunnaistettu kahteen tutkimusryhmään. Tieto tutkittavien tulehduskipulääkkeiden 
käytöstä saatiin reseptitietokeskuksesta. Eturauhassyövän riskiä ja kuolleisuutta tutkittiin seulotuilla 
verrattuna seulomattomiin tulehduskipulääkkeiden käyttäjillä ja ei-käyttäjillä käyttämällä 
ikävakioitua Cox:in Regressio – mallia.  
Tutkimustulokset olivat seuraavat: seulonta vähensi hyvin erilaistuneiden eturauhassyöpien 
(Gleason 6) ja paikallisten eturauhassyöpien diagnosointia tulehduskipulääkkeiden käyttäjillä 
verrattuna ei-käyttäjiin. Seulonta myös vähensi eturauhassyöpäkuolleisuutta 
tulehduskipulääkkeiden käyttäjillä, mutta ei ei-käyttäjillä. Tosin tulos ei ollut tilastollisesti 
merkitsevä. 
Tämänhetkisen käsityksemme mukaan olemme ensimmäistä kertaa osoittaneet eturauhassyövän 
seulonnan olevan tehokkaampaa tulehduskipulääkkeiden käyttäjillä verrattuna ei-käyttäjiin. 
Tutkimuksessamme totesimme, että kohdistamalla seulonnan tulehduskipulääkkeiden käyttäjiin, 
diagnosoidaan vähemmän hyvin erilaistuneita eturauhassyöpiä ja paikallisia eturauhassyöpiä. 
Seulonnan kohdistaminen saattaa vähentää kyseisten syöpämuotojen ylidiagnostiikkaa.   
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ABSTRACT 
Background: Finnish Randomized Study of Screening for Prostate Cancer  (FinRSPC), the largest 
component of the European Randomized Study of Screening for Prostate Cancer  (ERSPC), did 
show a smaller, non-significant reduction in prostate cancer-specific mortality by systematic PSA-
based screening compared with the ERSPC results overall. Non-steroidal anti-inflammatory drugs 
(NSAIDs) reduce inflammation and also PSA elevation due to intraprostatic inflammation. We 
explored whether NSAID usage modifies the mortality effect of PSA-based screening. 
Materials and methods: A cohort of 80,458 men from the FinRSPC were linked to a comprehensive 
national prescription database to obtain information on NSAID reimbursements prior to screening. 
Prostate cancer risk and mortality were compared between the FinRSPC screening arm and the 
control arm among NSAID users and non-users using age-adjusted Cox regression model. 
Results: Screening increased the detection of Gleason 6 (HR 1.79, 95% CI 1.62-1.97 and HR 1.28, 
95% CI 1.19-1.38) and localized prostate tumors (HR 1.50, 95% CI 1.39-1.63 and HR 1.04, 95% CI 
1.98-1.10) more among NSAID non-users than users, respectively (p for interaction < 0.001 for 
both). This difference was observed in each three screening rounds. Detection of metastatic PCa 
was similar in both NSAID users and non-users.  
Screening decreased prostate cancer mortality among men using NSAIDs (HR 0.79, 95% CI 0.67-
0.94), but not among non-users (HR 1.00, 95% CI 0.65-1.56), though the difference was not 
significant. Acetaminophen usage was not associated with similar risk differences. 
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Conclusions: Screening detected fewer well-differentiated, localized tumors among NSAID-users 
than non-users. This suggests that PSA screening may cause less overdiagnosis within this sub-
group. 
INTRODUCTION 
Benefits of screening for prostate cancer (PCa) with prostate-specific antigen (PSA) are 
controversial. Screening has been shown to be reduce PCa mortality, but it also causes 
overdiagnosis of indolent, early stage PCa and thus overtreatment1.  
In laboratory studies, non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce 
proliferation of PCa cells2, but in epidemiologic studies effects on prostate cancer risk or mortality 
have been conflicting3-5. On the other hand, several studies have demonstrated that NSAID usage 
lowers serum PSA6-8. Thus it could be presumed that NSAID usage may modify the effects of 
PSA-based screening. No studies to date have explored this topic.   
We investigated the efficacy of PCa screening between NSAID users and non-users in the Finnish 
Randomized Study of Screening for Prostate Cancer (FinRSPC). We explored the effect of 
screening on overall prostate risk, risk of high-risk disease and risk of PCa death by NSAID usage. 
The goal of our study is to determine whether NSAID usage modifies the effect of screening on 
detection of high-risk PCa or PCa mortality.  
MATERIALS & METHODS 
Study cohort 
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The Finnish Randomized Study of Screening for Prostate Cancer is the largest component of the 
multicenter ERSPC trial, including 80,458 men aged 55, 59, 63, or 67 years at the start of the 
study1,9. Men with PCa diagnosis at baseline were excluded. The remaining men were randomized 
into two trial arms. The screening arm (SA) consisted 31,866 men and the control arm (CA) 48,278 
men. Men in the screening arm were invited to their local outpatient clinic for PSA screening test.  
The screening was carried out at four-year intervals. The first screening round was performed in 
1996-1999, the second in 2000-2003 and the third in 2004-2007. After age 71, no re-invitations 
were made, thus men aged 67 at the beginning of the study were invited for screening only twice. 
Re-invitations stopped also if a person was diagnosed with PCa or had emigrated from the study 
area. Information on place of residence was obtained from the Population Register Center.  
If serum PSA was greater or equal to 4.0 ng/ml, the man was referred to a urological clinic for 
diagnostic examinations, including digital rectal examination (DRE), transrectal ultrasound and 
prostate biopsy. PSA 3.0-3.9 ng/mL was an indication for an additional test, which in 1996-1998 
was DRE and since 1999 a free/total PSA ratio with 16% as the cutoff. Men with any of the 
findings mentioned above were considered screen-positive and referred to a prostate biopsy. 
Information on prostate cancer cases detected in the control arm, as well as cases in the screening 
arm detected between the screening rounds and among non-participants was obtained from the 
comprehensive nation-wide Finnish Cancer Registry. Clinical information was abstracted from 
medical records. Information on prostate cancer cases included date of diagnosis, Gleason grade, 
TNM stage and primary treatment.  
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All deaths in Finland are registered by the cause of death registry maintained by Statistics Finland. 
The accuracy of recorded PCa deaths was validated by cause of death committee adjudicating the 
cause of death based on medical records, blinded in terms of official cause of death and trial arm.  
This study included PCa cases and deaths until the beginning of 2013.  
Information on NSAID usage 
Information on use of NSAIDs during 1995-2009 for the whole study cohort was obtained from the 
prescription database of the Social Insurance Institution (SII) of Finland. The information included 
the date, drug dose, amount of doses and amount of packages for each drug purchase. SII is a 
governmental agency operating under the Ministry of Health. It provides reimbursements for 
outpatient purchases of physician-prescribed medications for Finnish residents. Over-the-counter 
purchases are not reimbursed, thus not recorded. Additionally, drugs used during hospital inpatient 
periods are not recorded.  
Information on use of prescription-free NSAIDs (frequency, dose and duration) was collected in the 
third screening round by a questionnaire sent to men in the SA; 11,795 men participating at the third 
screening round, giving response rate of 92.6%. 
Statistical analysis 
Cox proportional hazards regression was used to analyze age-adjusted hazard ratios (HRs) and 95% 
confidence intervals (95% CIs) for PCa risk and mortality by trial arm.  
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PCa risk both overall and by biopsy Gleason grade and M stage at diagnosis were compared 
between the screening arm and control arm stratified by NSAID usage and cumulative duration of 
use during the study period. Only NSAID usage occurring before PCa diagnosis was included. 
Separate analyses were stratified by use of coxibs, acetaminophen and aspirin. Effect of PSA 
screening on risk of PCa death was also analyzed separately among NSAID users and non-users. 
Effect modification by NSAID usage was evaluated by adding an interaction term between NSAID 
usage and the trial arm to Cox regression model. 
For analyses on screening effects by screening round, NSAID usage for the whole study population 
was limited to usage that occurred in the time period before the screening round under analysis. 
Prostate cancer cases were limited to those detected at the time period before the initiation of next 
screening round. Prostate cancer deaths were limited to those occurring between screening and 
1.1.2013. 
Median PSA values were compared by NSAID usage at each screening round. Additionally, we 
evaluated the direction and magnitude of change in PSA among men who were not previous 
NSAID users, but started usage between the screening rounds. 
The ability of PSA to predict screen-detected PCa among men in the screening arm was tested with 
receiver operating characteristics (ROC) analysis. Only cases diagnosed within four years of 
screening (i.e. between consecutive screening rounds) were included. Area Under the Curve (AUC) 
from a model including age and PSA was compared to a model including additionally ever-use of 
NSAIDs as well as amount and duration of NSAID usage. The comparison was performed 
separately for all three screening rounds.  
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All statistical tests are two-sided. Analyses were carried out using IBM SPSS statistics 22 software 
(Chicago, IL, USA)  
RESULTS 
Baseline characteristics 
Population characteristics among NSAID users and non-users have been described in detail 
previously4. In short, prevalence of use for prescription NSAIDs was high in both study arms 
(77.7% screening arm, 74.7% control arm). NSAID users were also more likely to have used other 
drugs such as antidiabetic, antihypertensive and cholesterol-lowering drugs.  
Effect of screening on prostate cancer incidence among NSAID users and non-users 
Compared to the control arm, screening expectedly increased the overall PCa incidence, but less in 
NSAID users (HR 1.03, 95% CI 0.97-1.09) than in non-users (HR 1.45, 95% CI 1.34-1.57, p for 
interaction < 0.001) (Table 1). Analyses by type of NSAID (acetaminophen, acetylsalicylic acid and 
COX-inhibitors) showed a similar pattern as NSAIDs in general. Duration of NSAID usage further 
modified the effect of screening: among men who had more than two years of NSAID usage PSA 
screening did not increase the overall PCa incidence compared to the control arm (p for interaction 
< 0.001).  
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Also the effect of screening on incidence of Gleason 7-10 PCa depended on NSAID usage; 
screening lowered the incidence among NSAID users, but not among non-users (Table 1). 
Similarly, screening decreased incidence of metastatic PCa slightly more among NSAID users, 
although the difference to non-users was non-significant.  The effect of screening tended to be 
similar for each NSAID (Table 1). 
PSA screening and prostate cancer mortality by NSAID usage 
Screening reduced PCa mortality in NSAID users (HR 0.79, 95% CI 0.67-0.94), but not in non-
users (HR 1.00, 95% CI 0.65-1.56) (Table 2). However, the difference did not reach statistical 
significance. The duration of usage did not modify the effect of screening on PCa mortality. In 
separate analyses, effect of screening on prostate cancer mortality was also similar among aspirin, 
coxib and acetaminophen users and non-users (Table 2).  
Effect of screening on prostate cancer incidence and mortality by NSAID usage at each screening 
round  
Similar to the main analysis, screening increased PCa incidence less among NSAID users than 
among non-users at the first screening round (HR 1.99, 95% CI 1.64-2.41 and HR 2.56, 95% CI 
2.19-2.99, p for interaction 0.048) (Table 3). The difference in PCa incidence between NSAID users 
and non-users diminished at subsequent screening rounds, though it remained significant. 
Screening did not reduce PCa mortality significantly among NSAID users or non-users in the first 
or third screening rounds (Table 3). During the second round, screening lowered PCa mortality only 
among NSAID users (HR 0.73, 95% CI 0.59-0.91, p for interaction 0.06).  
12 
 
 
 
Effect of NSAID usage on PSA 
In the first screening round, the median PSA levels did not differ by NSAID usage (Table 4), but at 
the second and third screening rounds, men who started NSAID usage between the screening 
rounds had non-significantly lower median PSA compared to the non-users, especially in users 
whose cumulative amount and duration of usage exceeded the median.  The difference was largest 
in the third screening round. The median PSA increase from the previous measurement was lower 
among men who started NSAID usage between the screening rounds. The amount or duration of 
NSAID usage above median did not affect the median PSA change (Table 4). 
The median percentage of free PSA was lower in NSAID users compared to non-users in the first 
screening round, but higher on two subsequent screening rounds (Table 4). Percentage of free PSA 
increased more between the screening rounds among men who started NSAID usage (Table 4).  
PSA as predictor of PCa incidence and PCa death 
AUC for PSA and age in predicting PCa and PCa death in each screening round was not 
significantly different between NSAID users and non-users (Table 5).   
DISCUSSION 
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To our knowledge, our results suggest for the first time that PSA screening causes less 
overdiagnosis of localized, Gleason 6 PCa among NSAID users than non-users. The reduction in 
detection of Gleason 6 tumors was larger among those men who had used NSAIDs for more than 
two years, which supports a causal association not produced by unmeasured background factors or 
confounding by indication. 
Our finding of slower progression of median PSA between the screening rounds among men who 
started NSAID usage supports previous studies reporting PSA lowering-effect of NSAIDs. 6,7 At 
the same time we observed increases in the median percentage of free PSA among NSAID users. 
This led to lower proportion of screen-positive men among NSAID users.  The PSA effect 
diminished between the second and third screening rounds witch suggests that the impact of 
NSAIDs as a modifier of PSA values may decrease over time.  Previous studies have demonstrated 
that NSAIDs lower PSA in men with chronic prostatitis when used in combination with 
antibiotics7,8. Thus NSAIDs may decrease the likelihood of PSA elevation due to inflammation 
and thus improve the accuracy of PSA-based prostate cancer screening. However, in ROC analyses 
NSAID usage did not improve prediction of screen-detected cancer by age and PSA. Thus further 
studies will be needed on what type of PCa NSAIDs mostly affect.  
In the European Randomized Study of Screening for Prostate Cancer (ERSPC) a 21% reduction in 
PCa mortality was reported1. However, the result varied between the participating centers. In the 
Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC), the largest component of 
the ERSPC, a modest 10% risk decrease by screening was observed9, whereas in the Swedish part 
of ERSPC clear reduction in PCa mortality was found10. Differences in NSAID usage between the 
ERSPC centers may have been one factor behind the differing responses.  
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Systemic and intraprostatic inflammation can elevate serum PSA levels but the association with 
PCa risk is controversial11,12.  This makes serum PSA levels a controversial screening tool as 
elevated PSA leads to screen-positivity and results in prostate biopsies and often to overdiagnosis, 
i.e. detection of localized well-differentiated malignancies of without clinical significance. As 
NSAID use may reduce overdiagnosis associated with PSA screening, our results suggest that 
NSAID usage should be taken into account when considering targeted screening efforts. 
A strength of our study was that we could assess the effect of screening in a randomized setting. 
Also information on physician-prescribed NSAID usage was comprehensive and free of recall bias 
as it was collected from a national database which routinely collects information from all Finnish 
residents regardless of health status. Information on prescription based purchases is exceptionally 
detailed, allowing us to accurately evaluate cumulative NSAID usage even in separate screening 
rounds.  
A limitation in our study was that we did not have detailed information about prescription-free use 
of NSAIDs. Thus over-the-counter may have caused exposure misclassification and bias towards 
the null in our results. However, the exposure misclassification is unlikely to differ by screening 
trial arm, thus it may not have had a relevant effect.   
CONCLUSION 
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We have demonstrated that use of NSAIDs reduces detection of Gleason 6 tumors associated with 
PSA-based prostate cancer screening. Furthermore, our findings suggested a larger mortality 
reduction by screening among men on NSAIDs, though the difference was not significant. Future 
studies on the efficacy of prostate cancer screening should consider prevalence of NSAID usage in 
the study population as screening may be more accurate in NSAID users.  
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Table 1 Effect of screening on prostate cancer incidence overall and by stage and grade among users and non-users of non-steroidal anti-
inflammatory drugs. Study population of 78,615 men from the Finnish Randomized Study of Screening for Prostate Cancer 
 HR (95% CI) for prostate cancer in the FinRSPC screening arm compared to the control arm 
Subgroups: Overall PCa Gleason 6 Gleason 7-10 Localized PCa Metastatic PCa 
NSAID users      
None 1.45 (1.34-1.57) 1.79 (1.62-1.97) 1.04 (0.92-1.20) 1.50 (1.39-1.63) 0.84 (0.60-1.18) 
Any 1.03 (0.97-1.09) 1.28 (1.19-1.38) 0.79 (0.73-0.86) 1.04 (0.98-1.10) 0.63 (0.50-0.80) 
P for interaction < 0.001 < 0.001 < 0.001 < 0.001 0.163 
Years of usage  
less than 2 years 1.12 (1.04-1.20) 1.44 (1.31-1.59) 0.79 (0.71-0.88) 1.14 (1.06-1.23) 0.62 (0.46-0.83) 
more than 2 years 0.92 (0.85-1.00) 1.06 (0.94-1.20) 0.79 (0.71-0.90) 0.92 (0.84-1.01) 0.64 (0.44-0.94) 
Acetaminophen users      
None 1.20 (1.14-1.26) 1.49 (1.40-1.58) 0.88 (0.82-0.95) 1.23 (1.17-1.29) 0.67 (0.55-0.82) 
Any  0.86 (0.75-0.98) 1.07 (0.88-1.30) 0.73 (0.61-0.86) 0.86 (0.74-0.98) 0.81 (0.50-1.32) 
Years of usage 
less than 2 years 0.93 (0.81-1.08) 1.18 (0.95-1.47) 0.78 (0.65-0.94) 0.95 (0.81-1.11) 0.88 (0.50-1.53) 
more than 2 years 0.63 (0.47-0.84) 0.75 (0.49-1.14) 0.54 (0.37-0.79) 0.58 (0.42-0.79) 0.62 (0.22-1.74) 
Aspirin users      
None 1.17 (1.12-1.22) 1.45 (1.37-1.55) 0.87 (0.81-0.93) 1.19 (1.13-1.25) 0.67 (0.55-0.82) 
Any  1.01 (0.83-1.21) 1.40 (1.07-1.82) 0.69 (0.53-0.91) 1.05 (0.86-1.29) 1.03 (0.55-1.93) 
Years of usage 
less than 2 years 1.05 (0.84-1.31) 1.46 (1.06-2.01) 0.74 (0.53-1.02) 1.12 (0.87-1.43) 1.08 (0.51-2.26) 
more than 2 years 0.93 (0.66-1.30) 1.29 (0.81-2.04) 0.60 (0.36-0.99) 0.95 (0.66-1.36) 0.88 (0.26-3.02) 
Coxib users      
None 1.07 (1.01-1.12) 1.31 (1.21-1.40) 0.84 (0.78-0.91) 1.07 (1.01-1.14) 0.63 (0.50-0.79) 
Any 0.91 (0.81-1.01) 1.12 (0.95-1.31) 0.75 (0.65-0.88) 0.90 (0.79-1.01) 0.57 (0.35-0.92) 
Years of usage       
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less than 2 years 0.96 (0.84-1.10) 1.16 (0.95-1.41) 0.82 (0.69-0.99) 0.96 (0.83-1.12) 0.66 (0.38-1.16) 
more than 2 years 0.80 (0.65-0.98) 1.03 (0.77-1.36) 0.61 (0.47-0.81) 0.76 (0.61-0.95) 0.38 (0.14-0.99) 
 
 
Table 2 Effect of screening on prostate cancer –specific mortality among users and non-users of non-steroidal anti-inflammatory drugs. Study 
population of 78,615 men from the Finnish Randomized Study of Screening for Prostate Cancer. 
 
 HR (95% CI) for prostate cancer death in the FinRSPC screening arm compared to the control arm 
Pattern of users All NSAID users Acetaminophen users Aspirin users Coxib users 
None 1.00 (0.65-1.56) 0.78 (0.64-0.94) 0.81 (0.69-0.97) 0.82 (0.68-0.99) 
Any 0.79 (0.67-0.94) 0.92 (0.69-1.23) 0.85 (0.49-1.47) 0.80 (0.58-1.11) 
less than 2 years 0.67 (0.52-0.86) 0.75 (0.39-1.44) 0.83 (0.39-1.81) 0.94 (0.58-1.53) 
more than 2 years 0.75 (0.52-1.09) 0.53 (0.19-1.45) 1.03 (0.29-3.66) 0.26 (0.06-1.15) 
21 
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Table 3 Prostate cancer incidence and mortality in the FinRSPC screening arm compared to control arm by screening round among men 
who had used NSAIDs before the screening 
 PCa incidence  PCa mortality 
 Number of screening round  Number of screening round 
 1st 2nd 3rd  1st 2nd 3rd 
 HR (95% CI) HR (95% CI) HR (95% CI)  HR (95% CI) HR (95% CI) HR (95% CI) 
n of PCa cases 
(users/non-users) 
262/320 432/222 685/226 n of PCa deaths 
(users/non-
users) 
72/70 49/32 18/9 
NSAID usage 
before screening 
       
None 2.56 (2.19-2.99) 1.87 (1.68-2.09) 1.25 (1.15-1.35)  0.85 (0.69-1.06) 1.03 (0.78-1.36) 0.99 (0.67-1.48) 
Any 1.99 (1.64-2.41) 1.55 (1.41-1.70) 1.12 (1.07-1.18)  0.77 (0.60-0.99) 0.73 (0.59-0.91) 0.82 (0.65-1.04) 
P for interaction 0.048 0.010 0.038  0.55 0.06 0.40 
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Table 4 Median PSA and change in PSA value between screening round among NSAID users and non-users 
 1st screening round 2nd screening round 3rd screening round 
Initiation of 
NSAID use 
between 
screening 
rounds 
Median PSA n (%) of 
screen-
positive men 
Median PSA Median PSA 
change from 
previous 
screening 
n (%) of 
screen-
positive men 
Median PSA Median PSA 
change from 
previous 
screening 
n (%) of 
screen-positive 
men 
No 1.07 2,042 (18.6%) 1.33 0.26 (ref) 1,109 (16.7%) 1.46 0.13 (ref) 474 (14.7%) 
Yes 1.07 1,702 (17.6%) 1.30 0.23 1,940 (16.2%) 1.40 0.10 1,273 (13.4%) 
Total amount 
of usage above 
median 
1.07 810 (17.5%) 1.29 0.22* 
 
946 (15.9%) 1.37 0.08 619 (13.3%) 
Total duration 
of usage above 
median 
1.07 852 (17.9%) 1.28 0.21* 810 (15.7%) 1.35 0.07 478 (13.3%) 
 Free/total PSA 
ratio 
 Free/total PSA 
ratio 
Change in 
free/total PSA 
ratio 
 Free/total PSA 
ratio 
Change in 
free/total PSA 
ratio 
 
None 26.40  26.15 -0.25 (ref)  28.50 2.35 (ref)  
Any 26.02  26.30 0.28  28.90 2.60  
Total amount 
above median 
26.10  26.40 0.30*  29.00 2.60  
Total duration 
above median 
26.20  26.50 0.30*  29.20 2.70  
* P-value ≤ 0.01 for change in PSA among men who initiated NSAID usage between two screening rounds compared to men who did not. 
Calculated using linear regression with natural logarithm of the change in PSA or free/total PSA as the dependent variable and amount or 
duration of NSAID usage, age and use of 5-alpha-reductase inhibitors and antidiabetic medication use as the explanatory variables  
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Table 5 Median PSA and change in PSA value between screening round among NSAID users and non-users 
 1st screening round  
(1996-1999) 
2nd screening round  
(2000-2003) 
3rd screening round  
(2004-2008) 
NSAID 
usage* 
None Any None Any None Any 
n of PCa 
cases before 
next 
screening 
round 
564 527 976 2,123 1,841 6,135 
AUC (95% CI) 
for PCa risk 
0.87 (0.85-
0.89) 
0.87 (0.84-
0.90) 
0.80 (0.77-
0.82) 
0.78 (0.76-
0.80) 
0.77 (0.74-
0.81) 
0.76 (0.74-
0.78) 
       
n of PCa 
deaths after 
screening 
367 285 207 367 145 508 
AUC (95% CI) 
for PCa 
death 
0.74 (0.68-
0.79) 
0.76 (0.71-
0.82) 
0.74 (0.65-
0.82) 
0.77 (0.69-
0.84) 
0.81 (0.62-
1.00) 
0.86 (0.74-
0.98) 
* NSAID usage status before the screening 
 
